179417-69-7

Basic information

• Product Name: TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID
• Synonyms: TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID;Boc-DL-(2-methoxyphenyl)glycine;a-(Boc-amino)-2-methoxybenzeneacetic acid;Boc-RS-2-methoxyphenylglycine
• CAS NO: 179417-69-7
• Molecular Formula: C₁₄H₁₉NO₅
• Molecular Weight: 281.3
• Mol File: 179417-69-7.mol

Chemical Properties

• Boiling Point: 451.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.189±0.06 g/cm3(Predicted)
• PKA: 3.35±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID(179417-69-7)
• EPA Substance Registry System: TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID(179417-69-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 179417-69-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID is used as a building block for the synthesis of pharmaceutical compounds due to its ability to facilitate the creation of diverse drug molecules. Its t-Boc protecting group is particularly advantageous for controlling reactions in organic synthesis, ensuring the production of desired pharmaceutical products with precision and efficiency.
Used in Drug Development Research:
In the realm of drug development research, TERT-BUTOXYCARBONYLAMINO-(2-METHOXY-PHENYL)-ACETIC ACID is utilized as a valuable compound for exploring its potential applications. Its unique properties make it a promising candidate for the development of new drugs, contributing to advancements in medicinal chemistry and therapeutic interventions.

Upstream product

• 124-38-9 carbon dioxide 
• 1291065-82-1 C₂₅H₄₅NO₃Sn 
• 24424-99-5 di-tert-butyl dicarbonate 
• 271583-17-6 2-amino-2-(2-methoxyphenyl)acetic acid 

Downstream Products

• 1111734-24-7 [{(3,4-dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-carbamoyl}-(2-methoxyphenyl)-methyl]-carbamic acid tert-butyl ester 
• 1111731-80-6 ({(3,4-dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-carbamoyl}-phenyl-methyl)-carbamic acid tert-butyl ester 
• 1352721-81-3 methyl 2-(N-tert-butoxycarbonylamino)-2-(2-methoxylphenyl)acetate 
• 1201195-03-0 (R,S)-2-Amino-2-(2-methoxy-phenyl)-N-(6-methoxy-pyridin-3-yl)-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-acetamide 

Relevant articles and documents

Synthesis ofN-Boc-α-amino Acids from Carbon Dioxide by Electrochemical Carboxylation ofN-Boc-α-aminosulfones

Electrochemical reduction ofN-Boc-α-aminosulfones in DMF using an undivided cell equipped with a Pt plate cathode and an Mg rod anode under atmospheric pressure of bubbling carbon dioxide through the solution under constant current conditions resulted in a reductive C-S bond cleavage with elimination of benzenesulfinate ion generating the corresponding anion species followed by fixation of carbon dioxide to give the correspondingN-Boc-α-amino acids in moderate to good yields.

HETEROARYL DERIVATIVES

Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES

The invention relates to novel compounds of formula (I) which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS

The invention relates to novel compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

NOVEL COMPOUNDS

Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction.

Synthesis of arylglycine and mandelic acid derivatives through carboxylations of α-amido and α-acetoxy stannanes with carbon dioxide

Incorporation reactions of carbon dioxide (CO2) with N-Boc-α-amido and α-acetoxy stannanes were developed using CsF as a mild tin activator. Monoprotected α-amido stannanes could be used, and the corresponding arylglycine derivatives were obtained in moderate-to-high yields under 1 MPa (10 atm) of CO2 pressure. α-Acetoxy stannanes also underwent carboxylation to afford mandelic acid derivatives in excellent yields under ambient CO2 pressure. Both transformations enabled the synthesis of α-tertiary and α-quaternary carboxylic acid derivatives. In addition, the chirality of (S)-N-tert-butylsulfonyl-α- amido stannanes was transferred with up to 90% inversion of configuration at 100 °C.

MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to compounds of formulawherein Ar, R1, R2, R3, R4, R5, n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.